Compare Aurobindo Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ABBOTT INDIA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ABBOTT INDIA AUROBINDO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 19.8 52.7 37.5% View Chart
P/BV x 4.3 17.0 25.1% View Chart
Dividend Yield % 0.2 0.4 61.0%  

Financials

 AUROBINDO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
ABBOTT INDIA
Mar-19
AUROBINDO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs8308,834 9.4%   
Low Rs5275,458 9.7%   
Sales per share (Unadj.) Rs333.91,731.1 19.3%  
Earnings per share (Unadj.) Rs40.4211.9 19.0%  
Cash flow per share (Unadj.) Rs51.8219.9 23.5%  
Dividends per share (Unadj.) Rs2.5065.00 3.8%  
Dividend yield (eoy) %0.40.9 40.5%  
Book value per share (Unadj.) Rs237.1945.2 25.1%  
Shares outstanding (eoy) m585.9121.25 2,757.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.04.1 49.2%   
Avg P/E ratio x16.833.7 49.9%  
P/CF ratio (eoy) x13.132.5 40.3%  
Price / Book Value ratio x2.97.6 37.9%  
Dividend payout %6.230.7 20.2%   
Avg Mkt Cap Rs m397,569151,848 261.8%   
No. of employees `00017.93.5 512.3%   
Total wages/salary Rs m25,8494,356 593.4%   
Avg. sales/employee Rs Th10,956.910,555.5 103.8%   
Avg. wages/employee Rs Th1,447.71,249.9 115.8%   
Avg. net profit/employee Rs Th1,324.31,292.2 102.5%   
INCOME DATA
Net Sales Rs m195,63636,786 531.8%  
Other income Rs m1,5531,133 137.1%   
Total revenues Rs m197,18937,919 520.0%   
Gross profit Rs m39,5196,047 653.5%  
Depreciation Rs m6,680169 3,947.7%   
Interest Rs m2,62623 11,671.1%   
Profit before tax Rs m31,7676,989 454.6%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2692,485 292.5%   
Profit after tax Rs m23,6454,503 525.1%  
Gross profit margin %20.216.4 122.9%  
Effective tax rate %22.935.6 64.3%   
Net profit margin %12.112.2 98.7%  
BALANCE SHEET DATA
Current assets Rs m153,64527,610 556.5%   
Current liabilities Rs m120,4298,569 1,405.4%   
Net working cap to sales %17.051.8 32.8%  
Current ratio x1.33.2 39.6%  
Inventory Days Days13560 224.5%  
Debtors Days Days6427 232.5%  
Net fixed assets Rs m103,9091,057 9,831.6%   
Share capital Rs m586213 275.7%   
"Free" reserves Rs m138,32219,873 696.0%   
Net worth Rs m138,90820,086 691.6%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54429,409 899.5%  
Interest coverage x13.1311.6 4.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.3 59.1%   
Return on assets %9.915.4 64.5%  
Return on equity %17.022.4 75.9%  
Return on capital %23.834.9 68.3%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,316369 26,375.9%   
Fx outflow Rs m40,5894,918 825.2%   
Net fx Rs m56,727-4,549 -1,246.9%   
CASH FLOW
From Operations Rs m16,2204,991 325.0%  
From Investments Rs m-28,768-2,570 1,119.4%  
From Financial Activity Rs m19,191-1,428 -1,343.9%  
Net Cashflow Rs m6,656993 670.1%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.0 7.9 100.6%  
FIIs % 27.7 0.1 27,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.1 59.6%  
Shareholders   69,601 18,270 381.0%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUN PHARMA  ORCHID PHARMA  SANOFI INDIA  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 12, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS